Alexion's long-acting C5 inhibitor meets in Phase III

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said Thursday that ALXN1210, its long-acting formulation of Soliris eculizumab, met the co-primary and four key secondary endpoints in the Phase III ALXN1210-PNH-301 trial to treat paroxysmal nocturnal hemoglobinuria (PNH).

Read the full 343 word article

User Sign In